Drug Trial Radar · NCT07704892
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Oct 16, 2030
Study completion Dec 8, 2033
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.
Conditions
- Metabolic Dysfunction-associated Steatohepatitis
Interventions
Efimosfermin alfaDrug
Efimosfermin alfa (subcutaneous injection) will be administered.
PlaceboDrug
Placebo (subcutaneous injection) will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASHTime frame: At Week 96
Locations
39 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Little Rock, Arkansas · Recruiting
GSK Investigational Site
Arcadia, California · Recruiting
GSK Investigational Site
Arroyo Grande, California · Recruiting
GSK Investigational Site
Folsom, California · Recruiting
GSK Investigational Site
Montclair, California · Recruiting
GSK Investigational Site
Van Nuys, California · Recruiting
GSK Investigational Site
Cape Coral, Florida · Recruiting
GSK Investigational Site
Fort Myers, Florida · Recruiting
GSK Investigational Site
Hialeah, Florida · Recruiting
GSK Investigational Site
Homestead, Florida · Recruiting
GSK Investigational Site
Kissimmee, Florida · Recruiting
GSK Investigational Site
Lakeland, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Ocala, Florida · Recruiting
GSK Investigational Site
University Park, Florida · Recruiting
GSK Investigational Site
St Louis, Missouri · Recruiting
GSK Investigational Site
East Syracuse, New York · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Morehead City, North Carolina · Recruiting
GSK Investigational Site
Springboro, Ohio · Recruiting
GSK Investigational Site
Westlake, Ohio · Recruiting
GSK Investigational Site
Arlington, Texas · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Bellaire, Texas · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Humble, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
Waco, Texas · Recruiting
GSK Investigational Site
West Jordan, Utah · Recruiting
GSK Investigational Site
Manassas, Virginia · Recruiting
GSK Investigational Site
Seattle, Washington · Recruiting
GSK Investigational Site
Kawasaki-shi, Japan · Recruiting
GSK Investigational Site
Ōita, Japan · Recruiting
GSK Investigational Site
Ōgaki, Gifu, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.